Shares of Sorrento Therpt (SRNE) are trading -7% lower at a price of $2.58 at the time of this writing.

Sorrento Therpt has been trading between a 52-week high of $9.63 and a 52-week low of $1.15. The stock has a market cap of $1 Billion.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™.

Analysts’ Suggestions in the Limelight: Sorrento Therapeutics, Inc. (NASDAQ:SRNE), ChargePoint Holdings, Inc. (NYSE:CHPT)
Stock Equity 07-07-22

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical (NASDAQ:SRNE)
Seeking Alpha 07-07-22

Why Sorrento Therapeutics Stock Is Jumping Today
The Motley Fool 07-05-22

Sorrento Therapeutics Inc. (NASDAQ: SRNE) Stock Forecast For 2022: Bullish Signs Point To $16.00 Per Share
Marketing Sentinel 07-05-22

Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
GlobeNewswire 06-24-22